The Effects of Iloprost Infusion on Capillary Recruitment and Whole-body Glucose Uptake in Type 2 Diabetic Patients - a Cross-over Trial.
Iloprost, a stable prostacyclin analogue, is being investigated for its potential to enhance insulin sensitivity and glucose uptake in patients with Type 2 diabetes. Given the increasing prevalence of diabetes and the need for effective treatments, this study could position iloprost as a novel therapeutic option in a competitive market dominated by existing antidiabetic medications. The results may provide insights into iloprost's utility in improving metabolic outcomes, which could attract interest from pharmaceutical companies looking to expand their diabetes portfolios. However, the exclusion of patients with cardiovascular events may limit the generalizability of findings, necessitating further studies to confirm efficacy and safety in broader populations.
Indication: Diabetes Mellitus, Type 2
Modality: small molecule
Target: Insulin-mediated muscle capillary recruitment and whole-body glucose uptake.
Sponsor: Amsterdam UMC, location VUmc
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 15, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Insulin-mediated muscle capillary recruitment and whole-body glucose uptake.
View original source fields
Condition raw: Diabetes Mellitus, Type 2, Insulin Sensitivity/Resistance
Condition normalized: Diabetes Mellitus, Type 2, Insulin Sensitivity/Resistance
Modality raw: small molecule
Modality normalized: small molecule
Target raw: Insulin-mediated muscle capillary recruitment and whole-body glucose uptake.
Target normalized: Insulin-mediated muscle capillary recruitment and whole-body glucose uptake.